Vaccine Contract Manufacturing Industry Gains Momentum with Expanding Outsourcing Strategies
Author : violet Mac | Published On : 09 Jul 2026
The global vaccine contract manufacturing market was valued at USD 3.49 billion in 2025 and is projected to grow from USD 3.92 billion in 2026 to USD 10.02 billion by 2034, registering a CAGR of 12.45% during the forecast period (2026–2034). Increasing investments in vaccine research, rising outsourcing activities among pharmaceutical companies, and the growing demand for rapid, cost-efficient vaccine production are accelerating market expansion. The evolution of biologics manufacturing, mRNA technologies, and strategic partnerships between vaccine developers and contract manufacturing organizations (CMOs) continues to reshape the competitive landscape.
Key Highlights
- Market Size (2025): USD 3.49 Billion
- Forecast Market Size (2034): USD 10.02 Billion
- Forecast CAGR (2026–2034): 12.45%
- Largest Region: North America
- Fastest Growing Region: Asia-Pacific
- Largest Vaccine Type Segment: Sub-attenuated Vaccine
- Fastest Growing Vaccine Type Segment: Sub-attenuated Vaccine (CAGR 11.76%)
- Largest Service Segment: Fill/Finish Services
- Fastest Growing Service Segment: Fill/Finish Services (CAGR 12.78%)
Market Dynamics
Drivers
The vaccine contract manufacturing industry is witnessing remarkable momentum as pharmaceutical and biotechnology companies increasingly outsource manufacturing to reduce operational complexity, optimize production costs, and accelerate commercialization timelines. The growing prevalence of infectious diseases, expanding global immunization initiatives, and continuous innovation in vaccine technologies have intensified the need for highly specialized manufacturing capabilities. Contract manufacturers equipped with advanced production facilities, regulatory expertise, and scalable infrastructure are becoming indispensable partners for vaccine developers seeking operational flexibility.
In addition, the rapid advancement of biologics, recombinant vaccines, viral vector platforms, and next-generation mRNA technologies is encouraging pharmaceutical companies to collaborate with experienced CMOs that possess sophisticated manufacturing capabilities. These partnerships enable faster clinical development, efficient technology transfer, and reliable commercial-scale production while minimizing capital expenditure.
Restraints and Opportunities
Despite its impressive outlook, the market continues to face several operational challenges. Vaccine production requires strict regulatory compliance, extensive quality validation, highly controlled manufacturing environments, and significant capital investments. Complex technology transfer processes, supply chain disruptions, and stringent global regulatory standards can increase production timelines and operational costs for manufacturers.
However, the market presents substantial growth opportunities through expanding vaccine development pipelines, increasing government investments in healthcare preparedness, and growing demand for pandemic-response manufacturing capabilities. Emerging economies are also investing heavily in biopharmaceutical infrastructure, creating favorable conditions for regional contract manufacturing expansion. Continuous advancements in automation, single-use bioprocessing systems, and digital manufacturing technologies are expected to improve manufacturing efficiency while supporting long-term market growth.
Top Market Players
- Lonza Group
- Catalent Inc.
- Thermo Fisher Scientific Inc.
- FUJIFILM Diosynth Biotechnologies
- Cytovance Biologics
- IDT Biologika GmbH
- Recipharm AB
- Wuxi Biologics
- KBI Biopharma
- Jubilant HollisterStier LLC
Market Segmentation
By Vaccine Type
- Sub-attenuated Vaccine
- Inactivated Vaccine
- Toxoid Vaccine
- Recombinant Vaccine
- Others
By Service
- Fill/Finish
- Manufacturing
- Packaging
- Analytical & Quality Testing
- Others
By Application
- Human Vaccines
- Veterinary Vaccines
By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Unlock Full Report Insights and Strategic Analysis - https://straitsresearch.com/report/vaccine-contract-manufacturing-market
Gain comprehensive intelligence on emerging market opportunities, competitive benchmarking, regional growth outlook, technological advancements, investment trends, strategic developments, and detailed market forecasts. The complete report delivers in-depth segmentation analysis, company profiles, future growth prospects, and actionable business insights designed to support strategic decision-making for manufacturers, investors, healthcare organizations, and industry stakeholders seeking long-term competitive advantage.
About Us
Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.
Contact Us
Email: [email protected]
Tel:
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
